Haemonetics (HAE) Tops Q3 EPS by 10c; raises guidance

Haemonetics (NYSE: HAE) reported Q3 EPS of $1.04, $0.10 better than the analyst estimate of $0.94. Revenue for the quarter came in at $336 million versus the consensus estimate of $320.77 million.

GUIDANCE:

Haemonetics sees FY2024 EPS of $3.90-$4.00, versus the consensus of $3.89.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance